HGF Inhibitors
Common HGF Inhibitors include, but are not limited to ARQ 197 CAS 905854-02-6, Foretinib CAS 849217-64-7, INCB28060 CAS 1029712-80-8, Met Kinase Inhibitor CAS 658084-23-2 and JNJ-38877605 CAS 943540-75-8.
HGF inhibitors belong to a specific chemical class of compounds designed to target and inhibit the activity of Hepatocyte Growth Factor (HGF), also known as scatter factor. HGF is a cytokine that plays a critical role in various biological processes, including cell proliferation, migration, and tissue repair. It functions as a ligand for the c-Met receptor tyrosine kinase, activating downstream signaling pathways that regulate cell behavior and tissue homeostasis.
HGF inhibitors work by specifically targeting the HGF protein, interfering with its binding to the c-Met receptor and the subsequent activation of signaling pathways. By doing so, these inhibitors may modulate the cellular responses triggered by HGF, affecting processes such as cell growth, motility, and tissue regeneration. Research into HGF inhibitors is ongoing to unravel their precise mechanisms of action and explore their implications in understanding cellular communication and tissue remodeling. The study of HGF inhibitors contributes to a deeper understanding of the intricate mechanisms governing cell signaling and tissue dynamics.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ARQ 197 | 905854-02-6 | sc-364408 sc-364408A | 50 mg 200 mg | $712.00 $1920.00 | ||
ARQ 197 is a small molecule inhibitor that targets the c-Met receptor, which is activated by HGF. It binds to the c-Met receptor, preventing its activation by HGF and inhibiting downstream signaling pathways that promote cancer growth and metastasis. | ||||||
Foretinib | 849217-64-7 | sc-364492 | 5 mg | $129.00 | 6 | |
Foretinib, also known as GSK1363089, is an inhibitor of c-Met and other receptor tyrosine kinases. By targeting c-Met, Foretinib interferes with HGF-induced signaling pathways, suppressing the growth, survival, and metastasis of cancer cells driven by HGF-c-Met interactions. | ||||||
INCB28060 | 1029712-80-8 | sc-364510 sc-364510A | 10 mg 50 mg | $305.00 $750.00 | ||
INCB28060 is a selective c-Met inhibitor that targets the HGF-c-Met axis. It inhibits c-Met kinase activity, preventing downstream signaling that contributes to cell proliferation and migration. Capmatinib has shown promise in tumors with c-Met dysregulation, often associated with HGF-dependent activation. | ||||||
Met Kinase Inhibitor | 658084-23-2 | sc-204801 | 1 mg | $116.00 | 5 | |
Met Kinase Inhibitor is a small molecule inhibitor that targets c-Met, which is activated by HGF. It binds to c-Met, inhibiting its kinase activity and preventing HGF-induced signaling. SU11274's mechanism disrupts cancer-promoting pathways driven by the HGF-c-Met interaction, potentially limiting tumor growth and metastasis. | ||||||
JNJ-38877605 | 943540-75-8 | sc-364516 sc-364516A | 2 mg 10 mg | $126.00 $365.00 | 1 | |
JNJ-38877605 is an investigational c-Met inhibitor that targets HGF-c-Met signaling. It inhibits c-Met kinase activity, interfering with cancer-related pathways like cell survival and angiogenesis. JNJ-38877605's specificity for c-Met holds potential for targeting HGF-driven malignancies and overcoming resistance. | ||||||
BMS 777607 | 1025720-94-8 | sc-364438 sc-364438A | 10 mg 50 mg | $392.00 $1244.00 | 1 | |
BMS-777607 is a selective c-Met inhibitor that blocks HGF-c-Met signaling. It inhibits c-Met kinase activity, disrupting pathways associated with cancer cell growth, survival, and migration. BMS-777607's mechanism provides potential for intervention in cancers with aberrant HGF-c-Met interactions. | ||||||